Novo Nordisk Shares Face Critical Test Amid Institutional Exodus

Danish pharmaceutical leader Novo Nordisk is confronting a severe market downturn as major investors rapidly divest their holdings. The company’s stock has plummeted 58% from its peak levels and now approaches a crucial support threshold that could determine its near-term trajectory. This selling pressure follows management’s decision to significantly scale back annual performance expectations.

The core issue driving the selloff stems from disappointing operational developments. Novo Nordisk has substantially lowered its full-year 2025 guidance, now projecting revenue growth of just 8-11% at constant exchange rates, markedly below previous expectations.

Market analysts point to slowing momentum for the company’s flagship medications Wegovy and Ozempic as the primary concern. These former Read more...